力诺药包12月23日获融资买入374.21万元，融资余额1.51亿元

Core Viewpoint - Linuo Pharmaceutical Packaging Co., Ltd. experienced a decline in stock price and financial performance, with significant changes in financing and shareholder structure [1][2]. Financing Summary - On December 23, Linuo Pharmaceutical's stock fell by 1.48%, with a trading volume of 41.78 million yuan. The financing buy-in amount was 3.74 million yuan, while the financing repayment was 6.19 million yuan, resulting in a net financing outflow of 2.45 million yuan [1]. - As of December 23, the total financing and securities lending balance for Linuo Pharmaceutical was 151 million yuan, accounting for 3.65% of its market capitalization, indicating a high level compared to the past year [1]. - The company had no shares sold short or repaid on December 23, with a securities lending balance of 29,240 yuan, which is above the 90th percentile for the past year [1]. Financial Performance Summary - For the period from January to September 2025, Linuo Pharmaceutical reported a revenue of 721 million yuan, a year-on-year decrease of 13.22%, and a net profit attributable to shareholders of 50.88 million yuan, down 27.80% year-on-year [2]. - The company has distributed a total of 139 million yuan in dividends since its A-share listing, with 92.18 million yuan distributed over the past three years [2]. Shareholder Structure Summary - As of September 30, 2025, the number of shareholders for Linuo Pharmaceutical increased to 17,600, a rise of 58.60% from the previous period, while the average number of circulating shares per shareholder decreased by 36.94% to 13,571 shares [2]. - New institutional shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B, holding 3.8 million shares, and Green High Dividend Preferred Mixed A, holding 3.14 million shares, both ranking among the top ten circulating shareholders [2].